{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:24:33Z","timestamp":1788344673826,"version":"build-2803163510"},"reference-count":65,"publisher":"Informa UK Limited","issue":"26","funder":[{"name":"scientific advisory board for Merck"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.2217\/fon-2022-0926","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T08:45:26Z","timestamp":1695372326000},"page":"1803-1809","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Cerebrospinal Fluid-Administered Therapies for Leptomeningeal Metastases from Solid Tumors"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1729-0142","authenticated-orcid":false,"given":"Archit B","family":"Baskaran","sequence":"first","affiliation":[{"name":"Resident, Department of Neurology,The University of Chicago Medicine, \rChicago, \rIL 60637, \rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5292-2822","authenticated-orcid":false,"given":"Ankush","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Section Head of Neuro-Oncology, Department of Neurology, Medicine, &amp; Human Oncology, University of Wisconsin School of Medicine &amp; Public Health,Madison, \rWI 53705, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5923-0677","authenticated-orcid":false,"given":"Priya","family":"Kumthekar","sequence":"additional","affiliation":[{"name":"Department of Neurology, Lou &amp; Jean Malnati Brain Tumor Institute,Northwestern University, \rChicago, \rIL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9029-1248","authenticated-orcid":false,"given":"Adrienne","family":"Boire","sequence":"additional","affiliation":[{"name":"Geoffrey Beene Junior Faculty Chair, Department of Neurology, Human Oncology &amp; Pathogenesis Program, Brain Tumor Center,Memorial Sloan Kettering Cancer Center, \rNew York, \rNY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9352-5396","authenticated-orcid":false,"given":"Rimas V","family":"Lukas","sequence":"additional","affiliation":[{"name":"Neuro-Oncology Division, Associate Professor, Regional Ambulatory Medical Director, Neurology, Department of Neurology, Lou &amp; Jean Malnati Brain Tumor Institute,Northwestern University, \rChicago, \rIL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"issue":"4","key":"e_1_3_3_3_1","first-page":"484","article-title":"Leptomeningeal metastases: a RANO proposal for response criteria","volume":"19","author":"Chamberlain M","year":"2017","unstructured":"Chamberlain M , JunckL, BrandsmaDet al. Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol.19(4), 484\u2013492 (2017).","journal-title":"Neuro Oncol."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70034-6"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116706"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-021-03924-2"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anclin.2007.07.001"},{"issue":"2","key":"e_1_3_3_8_1","first-page":"26","article-title":"Cerebrospinal fluid (CSF) directed antineoplastic agents: a review of current knowledge","volume":"2","author":"Molander L","year":"2015","unstructured":"Molander L , CarawayC, LinderbeckL, LaberDA. Cerebrospinal fluid (CSF) directed antineoplastic agents: a review of current knowledge. J. Cancer Prev. Curr. Res.2(2), 26 (2015).","journal-title":"J. Cancer Prev. Curr. Res."},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00509"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197507242930402"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjae.2019.11.002"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4047617"},{"issue":"5","key":"e_1_3_3_13_1","first-page":"885","article-title":"Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study","volume":"61","author":"Gutin PH","year":"1977","unstructured":"Gutin PH , LeviJA, WiernikPH, WalkerMD. Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study. Cancer Treat. Rep.61(5), 885\u2013887 (1977).","journal-title":"Cancer Treat. Rep."},{"issue":"7","key":"e_1_3_3_14_1","first-page":"1549","article-title":"Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate","volume":"66","author":"Trump DL","year":"1982","unstructured":"Trump DL , GrossmanSA, ThompsonG, MurrayK, WharamM. Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate. Cancer Treat. Rep.66(7), 1549\u20131551 (1982).","journal-title":"Cancer Treat. Rep."},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.1.68"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.10.1655"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1990.345"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910701)68:1<88::AID-CNCR2820680118>3.0.CO;2-5"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.1.143"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1993.00540030027009"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.561"},{"issue":"3","key":"e_1_3_3_22_1","first-page":"189","article-title":"Tolerance and cerebrospinal fluid pharmacokinetics of intrathecally administered human natural interleukin-2: a phase I trial","volume":"4","author":"R\u00f6sener M","year":"1993","unstructured":"R\u00f6sener M , SchwuleraU, MenkeGet al. Tolerance and cerebrospinal fluid pharmacokinetics of intrathecally administered human natural interleukin-2: a phase I trial. Eur. Cytokine Netw.4(3), 189\u2013195 (1993).","journal-title":"Eur. Cytokine Netw."},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01052668"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1995.6.1-55"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-79952-5_10"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-199711000-00005"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1764::AID-CNCR24>3.0.CO;2-1"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.55.4.506"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005996606073"},{"issue":"11","key":"e_1_3_3_30_1","first-page":"3394","article-title":"A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors","volume":"5","author":"Glantz MJ","year":"1999","unstructured":"Glantz MJ , JaeckleKA, ChamberlainMCet al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res.5(11), 3394\u20133402 (1999).","journal-title":"Clin. Cancer Res."},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006373905428"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/1096-911X(20001201)35:6<716::AID-MPO51>3.0.CO;2-0"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1574"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hye055"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015752331041"},{"issue":"5","key":"e_1_3_3_36_1","first-page":"3057","article-title":"Intrathecal chemotherapy in carcinomatous meningitis from breast cancer","volume":"22","author":"Orlando L","year":"2002","unstructured":"Orlando L , CuriglianoG, ColleoniMet al. Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. Anticancer Res.22(5), 3057\u20133059 (2002).","journal-title":"Anticancer Res."},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.053"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11449"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.08.012"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.053"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1227\/01.NEU.0000166543.45294.F6"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.1807"},{"issue":"11","key":"e_1_3_3_43_1","first-page":"1799","article-title":"Phase I study of intrathecal chemotherapy with NS-101 for leptomeningeal carcinomatosis in Japan","volume":"34","author":"Nakagawa H","year":"2007","unstructured":"Nakagawa H , TamuraM, FukushimaY, MajimaS, YamadaK. Phase I study of intrathecal chemotherapy with NS-101 for leptomeningeal carcinomatosis in Japan. Gan To Kagaku Ryoho34(11), 1799\u20131805 (2007).","journal-title":"Gan To Kagaku Ryoho"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-006-9218-x"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-007-9340-4"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0601-x"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2007-059"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-007-9511-3"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq232"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24921"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e3182549643"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0199"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30214"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.02.032"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2019.04.004"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz201"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03555-z"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.04.018"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13738"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25859-y"},{"issue":"1","key":"e_1_3_3_61_1","first-page":"112","article-title":"Clinical trials on intrathecal pemetrexed treated leptomeningeal metastases from solid tumors","volume":"44","author":"Pan ZY","year":"2022","unstructured":"Pan ZY , SongYY, JiangTC, YangX, YangGZ. Clinical trials on intrathecal pemetrexed treated leptomeningeal metastases from solid tumors. Zhonghua Zhong Liu Za Zhi44(1), 112\u2013119 (2022).","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac195"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0918-0"},{"key":"e_1_3_3_64_1","unstructured":"Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases (ReSPECT-LM) . https:\/\/clinicaltrials.gov\/study\/NCT05034497 (Accessed 23August2023)."},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01148"},{"key":"e_1_3_3_66_1","unstructured":"A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis . https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05184816 (Accessed 23August2023)."},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz2193"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0926","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:47:41Z","timestamp":1719125261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":65,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.2217\/fon-2022-0926"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0926","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}